US Infant Formula Safety Questions Don’t Include Cronobacter National Reportable Disease Listing

FDA submitted four questions for USDA committee's advice on strengthening prevention of cronobactera contaminations such as problem leading to Abbott facility shutdown earlier in 2022 and supply shortage still affecting US. "High mortality rate of infants infected with cronobacter sakazakii should be enough for consumers expect this issue to receive an urgent response,” Stop Foodborne Illness CEO Mitzi Baum tells FDA and USDA.

• Source: Shutterstock

Numerous questions remain unanswered about preventing further problems with cronobacter bacteria contamination in infant formula marketed in the US, but one answer the Food and Drug Administration and food safety advocates suggest is requiring national disease reporting for cronobacter.

The FDA has submitted four questions (see below) to the Department of Agriculture's National Advisory Committee on Microbiological Criteria for Foods for advice on strengthening prevention of cronobacter contaminations such as the problem at an Abbott manufacturing facility

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Supply Chain

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

Rapidly Changing Market Demands Quick Study From Consumer Health, Personal Care Marketers

 

“It is shifting so quickly. It's shifting underneath our feet,” says NielsenIQ wellness VP Sherry Frey. Even comparing the past year to the preceding eight, “it's just accelerating quicker and quicker, and one of the biggest areas is online.”

China Distribution Disruption Drags Kenvue Results

 

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

Tariff War Should Steer US Firms To Mapping Out North American Supply Chains

 

Supplies from Mexico and Canada could become even more important to US firms as well as more reliable than their current systems, says Rob Handfield, Bank of America distinguished professor of supply chain management at NC State.

More from HBW Insight

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

Shiseido’s Key Priorities: Recover Drunk Elephant, Accelerate NARS Amid US Prestige Slowdown

 

Shiseido’s Drunk Elephant premium skin care range – acquired in 2019 – and its NARS brand dragged sales in the Americas region down almost 20% in the first quarter, the firm reported in a 12 May earnings presentation.

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.